These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19001107)

  • 1. Vancomycin ototoxicity: a reevaluation in an era of increasing doses.
    Forouzesh A; Moise PA; Sakoulas G
    Antimicrob Agents Chemother; 2009 Feb; 53(2):483-6. PubMed ID: 19001107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is vancomycin ototoxicity a significant risk?
    Shields RK; Martello JL; Potoski BA
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4572; author reply 4572-3. PubMed ID: 19770289
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term vancomycin use had low risk of ototoxicity.
    Humphrey C; Veve MP; Walker B; Shorman MA
    PLoS One; 2019; 14(11):e0224561. PubMed ID: 31693679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice.
    Elting LS; Rubenstein EB; Kurtin D; Rolston KV; Fangtang J; Martin CG; Raad II; Whimbey EE; Manzullo E; Bodey GP
    Cancer; 1998 Dec; 83(12):2597-607. PubMed ID: 9874468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of an AUC
    Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attention to age: similar dosing regimens lead to different vancomycin levels among older and younger patients.
    Yahav D; Abbas M; Nassar L; Ghrayeb A; Shepshelovich D; Kurnik D; Leibovici L; Paul M
    Age Ageing; 2019 Dec; 49(1):26-31. PubMed ID: 31711101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
    Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
    Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: selected case studies.
    Fausti SA; Rappaport BZ; Schechter MA; Frey RH; Ward TT; Brummett RE
    Am J Otolaryngol; 1984; 5(3):177-82. PubMed ID: 6742338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of adverse reactions associated with vancomycin therapy.
    Sorrell TC; Collignon PJ
    J Antimicrob Chemother; 1985 Aug; 16(2):235-41. PubMed ID: 3934126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
    Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M
    Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy.
    Wong-Beringer A; Joo J; Tse E; Beringer P
    Int J Antimicrob Agents; 2011 Feb; 37(2):95-101. PubMed ID: 21130609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.
    Lodise TP; Lomaestro B; Graves J; Drusano GL
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1330-6. PubMed ID: 18227177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensorineural hearing loss associated with intrathecal vancomycin.
    Klibanov OM; Filicko JE; DeSimone JA; Tice DS
    Ann Pharmacother; 2003 Jan; 37(1):61-5. PubMed ID: 12503934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China.
    Dong MH; Wang JW; Wu Y; Chen BY; Yu M; Wen AD
    Int J Infect Dis; 2015 Aug; 37():125-8. PubMed ID: 26159843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.
    Garinis AC; Cross CP; Srikanth P; Carroll K; Feeney MP; Keefe DH; Hunter LL; Putterman DB; Cohen DM; Gold JA; Steyger PS
    J Cyst Fibros; 2017 May; 16(3):401-409. PubMed ID: 28238634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity.
    Rostas SE; Kubiak DW; Calderwood MS
    Clin Ther; 2014 Jul; 36(7):1098-101. PubMed ID: 24931573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
    Burgess LD; Drew RH
    Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.
    Cano EL; Haque NZ; Welch VL; Cely CM; Peyrani P; Scerpella EG; Ford KD; Zervos MJ; Ramirez JA; Kett DH;
    Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ototoxicity of vancomycin and analogues.
    Brummett RE
    Otolaryngol Clin North Am; 1993 Oct; 26(5):821-8. PubMed ID: 8233491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss.
    de Hoog M; van Zanten BA; Hop WC; Overbosch E; Weisglas-Kuperus N; van den Anker JN
    J Pediatr; 2003 Jan; 142(1):41-6. PubMed ID: 12520253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.